Share prices of JMI Syringe and Medical Devices Limited saw ‘abnormal’ rise over the weeks without having any fundamental reason, prompting the securities regulator to bring the company under its scanner.
The company’s share prices fell for the first time Sunday before witnessing continuous rises since its listing with the Dhaka Stock Exchange on June 19, 2013. The company was listed with the Chittagong stock Exchange (CSE) on 12 January, 2004.
In its first trading day at DSE, JMI Syringe shares closed at Tk35.5 each, which rose by 276% to Tk133.5 as of July 11, before closing a little down at Tk122.5 each Sunday.
“Such irrational price movement of the company has come to the notice of the commission,” Saifur Rahman, executive director of Bangladesh Securities and Exchange Commission, told the Dhaka Tribune. “It is now under investigation.”
Meanwhile, the Chittagong Stock Exchange (CSE) is also aware of the unusual price hike of the company as they already launched an investigation, said Syed Sajid Hossain, Chief Executive Officer of the port city bourse.
He said the CSE is monitoring the price movement to see whether there is any manipulation.
“The price remains stable at CSE, but skyrocketed after being listed with the Dhaka Stock Exchange (DSE) as a section of big players bought most of the stocks,” said a high official of DSE, requesting anonymity.
The company’s financial statements posted in its own website are at variance with the DSE website, brining confusion among the investors.
According to its first quarter unaudited report posted in its website, the company showed EPS (earning per share) Tk0.27 and reported profit of Tk2.9m.
But the company’s first quarter unaudited report ended on March 31 posted in the DSE website showed that EPS of the company stood at Tk0.08 and made profit of Tk0.92m, a sharp decrease of more than 57% in the same period a year ago.
“I have bought 1,000 shares of JMI at Tk40 each at the advice of my ‘guru’ who told me that price of the company will reach over Tk150,” said a retailer, wishing anonymity.
Asked about the price hike or about the company’s fundamental, he replied that fundamental did not reflect in the price movement.
According to CSE statistics, the company declared 12% cash dividend for its shareholders in 2012, 10% in 2011, 7.5% in 2008 and 2009, and 5% in 2007.
A section of market players has bought the shares and is playing with it just to influence the market to become instable and make windfall profits, said a DSE member, requesting anonymity.
He said the BSEC is not playing its due role, creating opportunity for many to make money by swindling innocent investors.
The company was established in April 1999 in Bangladesh with joint collaboration of Republic of Korea to produce export quality Auto-Disable (AD) Syringe, all kinds of Disposable Syringes and Medical Devices.



